

Connecticut Medicaid P&T Meeting Minutes – May 11, 2011

The meeting started at 6:00 pm

Attendance

Present Members:

Carl Sherter, MD
Lawrence Sobel, RPh
Emmett Sullivan, RPh
Stella Cretella
Richard Carbray Jr., RPh
Hilda Slivka, MD
Charles Thompson, MD
Manage Nissanka, MD
Elizabeth Rodriguez, RN

DSS:

Evelyn Dudley
Jason Gott, RPh
Jim Zakszewski, RPh

Absent Members:

Tsompika Apostolidis
Eric Einstein, MD
Ezra Griffith, MD

HP/Provider Synergies:

Chris Andrews, Pharm D
Deborah Gallagher
Ellen Arce, RPh
Mark Synol, RPh
Heather Kissinger, Pharm D
Melissa Chandler

Opening remarks:

Dr. Carl Sherter informed the committee members of the resignation of co-chair Peggy Manning-Memoli, Pharm D.

The committee thanks Ms. Memoli for her years of service.

Evelyn Dudley Pharmacy Programs Manager, DSS informed the committee members of the new Commissioner of the Department of Social Services, Roderick L. Bremby.

Approval of minutes:

Committee members approved the meeting minutes from the March 3, 2011 meeting.

Public Presentations:

Immunosuppressants – Prograf
Immunosuppressants
Hepatitis Agents – Interferons
Multiple Sclerosis Agents – Ampyra
Multiple Sclerosis Agents
Neulasta and Prolia
Antiemetics – Zuplenz
Colony Stimulating Factors
Androgenic Agents – Testosterone
Replacement Therapy

J. Mario Affonso, Astellas Pharma
Eric M. Tichy, Pharm D, Yale New Haven Hospital*
Dr. Martin Hoffman*
Rushmi Mathur, Pharm D
Dr. Jeffrey Gross MD*
Michael Masamitsu, Pharm D, Amgen
Diane Racicot MBA, Strativa Pharmaceuticals
Dr. Dinesh Kapur, President CT Oncology Assoc.*
Dr. Ilja Hulinsky*

Opiate Dependence Treatments
Growth Hormone – Norditropin Flexpro
Public Presentations cont.:

Dr. Samuel M. Silverman MD
Cheryl Pryor, Pharm D, Novo Nordisk

PAH Agents – Letairis
Oral Antifungals – Oravig
Antibiotics, Inhaled – Cayston
Anticoagulants – Pradaxa
Platelet Aggregation Inhibitors – Effient
Humulin Insulins
Onglyza and Kombiglyze XR

Ali H. Toumadj, Pharm D, Gilead Sciences
Diane Racicot, MBA, Strativa Pharmaceuticals
Ali H. Toumadj, Pharm D, Gilead Sciences
Susan Wood PhD., Boehringer Ingelheim
Shawn Boykin, PhD., Eli Lilly and Co.
Shawn Boykin, PhD., Eli Lilly and Co.
Amy Dalsani, Pharm D, Bristol-Myers Squibb

New Generics:

Chris Andrews informed the committee members regarding the following new generic products:

- Nonpreferred
 - epinastine (Elestat)
 - latanoprost (Xalatan)
 - methylphenidate ER (Concerta)
 - sulfacetamide / sulfur (Sumaxin TS)

The Committee motioned to approve and accept Provider Synergies' recommendations. The motion was passed unanimously.

Therapeutic Class Reviews:

Acne Agents, topical

Chris Andrews presented the evaluation and recommendation for this class. He noted that Differin is now available as a generic cream and gel. The brand has also introduced a lotion. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Slivka seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Azelex (Topical), Benzaclin (Topical), benzoyl peroxide (Topical), clindamycin phosphate (Topical), Differin (Topical), EpiDuo (Topical), erythromycin (Topical), Retin A Micro (Topical), sulfacetamide (Topical), tretinoin (Topical)*
- **OFF Medicaid PDL:** *Acanya (Topical), Aczone (Topical), adapalene Cream (Topical), adapalene Gel (Topical), Akne-Mycin (Topical), Atralin (Topical), Benzefoam (Topical), Clarifoam EF (Topical), Clinac BPO (Topical), Clindagel (Topical), clindamycin/benzoyl peroxide (Topical), Duac (Topical), erythromycin-benzoyl peroxide (Topical), Evoclin (Topical), Inova (Topical), Nuox (Topical), SE BPO (Topical), sodium sulfa-sulfur-meratan (Topical), sulfacetamide/sulfur (Topical), Sumaxin TS (Topical), Tazorac (Topical), Veltin (Topical), Ziana (Topical)*

Analgesics, NarcoticLong

Chris Andrews presented the evaluation and recommendation for this class. He also noted that Oxycontin has been reformulated to prevent immediate access to the full dose of oxycodone by various means. King pharmaceuticals announced a recall of all Embeda NDCs due to stability issues in March of 2011. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *fentanyl (Transderm), Kadian (Oral), methadone (Oral), morphine ER (Oral), tramadol ER (Oral)*

- **OFF Medicaid PDL:** *Avinza (Oral), Butrans (Transderm), Duragesic Matrix (Transderm), Embeda (Oral), Exalgo (Oral), Opana ER (Oral), oxycodone ER (Oral), Oxycontin (Oral), Oxycontin Reformulated (Oral), Ryzolt (Oral), Ultram ER (Oral)*

Analgesics, Narcotics Short

Chris Andrews presented the evaluation and recommendation for this class. He also noted that the FDA has recommended to manufacturers of propoxyphene products that those products be removed from the market and from this review. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Thompson seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *apap/codeine (Oral), butalbital compound w/codeine (Oral), codeine (Oral), dihydrocodeine/apap/caffeine (Oral), hydrocodone/apap(Oral), hydrocodone/ibuprofen (Oral), hydromorphone (Oral), meperidine (Oral), morphine IR (Oral), oxycodone (Oral), oxycodone/apap (Oral), oxycodone/asa (Oral), oxycodone/ibuprofen (Oral), pentazocine/apap (Oral), tramadol (Oral), tramadol/apap (Oral), Trezix (Oral),*
- **OFF Medicaid PDL:** *Abstral (Sublingual), Dilaudid Liquid (Oral), Fentanyl (Buccal), Fentora (Buccal), Hycet (Oral), Ibudone (Oral), Levorphanol (Oral), Nucynta (Oral), Onsolis (Buccal), Opana (Oral), oxymorphone (Oral), pentazocine/naloxone (Oral), Reprexain (Oral), Rybix ODT (Oral), Zamicet (Oral), Zolvit (Oral)*

Androgenic Agents

Chris Andrews presented the evaluation and recommendation for this class. He also noted that Androgel is now owned by Abbott. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Androderm (Transderm), Androgel (Transderm)*
- **OFF Medicaid PDL:** *Fortesta (Transderm), Testim (Transderm)*

Angiotensin Modulators – Combinations

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Tarka is now available as a generic. Recent studies have also indicated the increased effectiveness of combination agents when compared to single therapy. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Thompson seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *amlodipine/benazepril (Oral), Azor/Tribenzor (Oral), Exforge/Exforge HCT (Oral), Valtuna (Oral),*
- **OFF Medicaid PDL:** *Lotrel (Oral), Tekamlo/Amturide (Oral), trandolapril/verapamil (Oral), Twynsta (Oral)*

Angiotensin Modulators

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Cozaar and Hyzaar are now available as generics. The 2010 ADA and American Stroke Association continue to recommend that diabetic patients receive ACEIs or ARBs for treatment of HTN, to reduce risk of stroke, and to delay the progression of diabetic neuropathy. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Avapro/Avalide (Oral), benazepril/hctz (Oral), captopril/hctz (Oral), Diovan/HCT (Oral), enalapril/hctz (Oral), fosinopril/hctz (Oral), lisinopril/hctz (Oral), losartan/hctz (Oral), moexipril/hctz (Oral), quinapril/hctz (Oral), ramipril (Oral), trandolapril (Oral)*
- **OFF Medicaid PDL:** *Atacand/HCT(Oral), Benicar/Benicar HCT (Oral), Micardis/Micardis HCT (Oral), perindopril (Oral), Tekturna/Tekturna HCT (Oral), Teveten/Teveten HCT (Oral)*

Antibiotics, GI

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 2010 CDC STD treatment guidelines continue to recommend metronidazole and Tindamax among options for bacterial vaginosis and trichomoniasis. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL with Dr. Silvka seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Alinia (Oral), metronidazole (Oral), neomycin (Oral), Tindamax (Oral), tinidazole (Oral)*
- **OFF Medicaid PDL:** *Flagyl ER (Oral), Vancocin HCL (Oral), Xifaxan (Oral)*

Antibiotics, Inhaled

Chris Andrews presented the evaluation and recommendation for this class. It was noted that there has been no new significant clinical updates to this class. Dr. Sherter recommended adding both agents in the class as preferred. Dr. Silvka motioned to approve and accept recommendations with both Tobi and Cayston as preferred agents, with Dr. Thompson seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Cayston (Inhalation), TOBI (Inhalation)*
- **OFF Medicaid PDL:** *None*

Antibiotics, Topical

Chris Andrews presented the evaluation and recommendation for this class. It was noted that there has been no new significant clinical updates to this class. Dr. Silvka motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *gentamicin sulfate (Topical), mupirocin ointment (Topical)*
- **OFF Medicaid PDL:** *Altabax (Topical), Bactroban Cream (Topical)*

Antibiotics, Vaginal

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 2010 CDC STD treatment guidelines continue to list vaginal formulation of metronidazole and clindamycin as options for the treatment of bacterial vaginosis. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Cleocin Ovules (Vaginal), clindamycin (Vaginal) metronidazole (Vaginal), Vandazole (Vaginal)*
- **OFF Medicaid PDL:** *Clindesse (Vaginal), Metrogel (Vaginal)*

Anticoagulants

Chris Andrews presented the evaluation and recommendation for this class. It was noted that this class now includes oral agents. Also Lovenox is now available as a generic. Dr. Sherter recommended adding Pradaxa as a preferred agent in the class. Dr. Silvka motioned to approve and accept Provider Synergies'

recommendations and add Pradaxa as a preferred agent. Dr. Thompson seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Arixtra (Subcutane.), Fragmin (Subcutane.), Lovenox (Subcutane.), Pradaxa (Oral), warfarin (Oral)*
- **OFF Medicaid PDL:** *enoxaparin (subcutane.), Innohep (Subcutane.)*

Antiemetics

Chris Andrews presented the evaluation and recommendation for this class. It was noted that there has been no new significant clinical updates to this class. Dr. Thompson motioned to approve and accept Provider Synergies' recommendations with the addition of Ondansetron ODT and Ondansetron solution as preferred agents. Dr. Slivka seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Emend (Oral), Marinol (Oral), ondansetron Tablets (Oral), ondansetron ODT (Oral), ondansetron solution (Oral)*
- **OFF Medicaid PDL:** *Anzemet (Oral), Cesamet (Oral), dronabinol (Oral), granisetron (Oral), Sancuso (Transdermal), Zuplenz (Oral)*

Antifungals, Oral

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Vfend is now available as a generic. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Dr. Slivka seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *fluconazole (Oral), griseofulvin suspension (Oral), Gris-Peg (Oral), ketoconazole (Oral), nystatin (Oral), terbinafine (Oral)*
- **OFF Medicaid PDL:** *Ancoban (Oral), Grifulvin V Tablets (Oral), itraconazole (Oral), Lamisil Granules (Oral), Noxafil (Oral), Oravig (Buccal), Sporanox Solution (Oral), Terbinex (Miscell), Vfend (Oral), voriconazole tablets (Oral)*

Antifungals, Topical

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Nuzole is miconazole 2% cream. Ketocon + Plus is ketoconazole 2% cream co-packaged with HCT 1% gel. Pediaderm AF is nystatin 100,000 units/g cream. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *clotrimazole RX (Topical), clotrimazole-betamethasone (Topical), econazole (Topical), ketoconazole (Topical), ketoconazole shampoo (Topical), nystatin (Topical), nystatin-triamcinolone (Topical)*
- **OFF Medicaid PDL:** *Bensal HP (Topical), ciclopirox CR/Susp/Gel (Topical), ciclopirox Shampoo (Topical), ciclopirox solution (Topical), CNL 8 (Topical), Ertaczo (Topical), Exelderm (Topical), Extina (Topical), Ketocon + Plus (Topical), Lamisil Solution (Topical), Mentax (Topical), Naftin (Topical), Nuzole (Topical), Oxistat (Topical), Pediaderm AF (Topical), Vusion (Topical), Xolegel (Topical)*

Antimigraine Agents, Triptans

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Amerge is now available as a generic. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Imitrex (Subcutane.), Imitrex (Nasal), Relpax (Oral), sumatriptan (Oral)*
- **OFF Medicaid PDL:** *Axert (Oral), Cambia (Oral), Frova (Oral), Imitrex (Oral), Maxalt Tablets (Oral), Maxalt MLT (Oral), sumatriptan (Nasal), sumatriptan (Subcutane.), Treximet (Oral), Zomig (Nasal), Zomig/Zomig ZMT (Oral)*

Antiparasitics

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 2010 American Academy of Pediatrics Head lice Guidelines recommend OTC permethrin 1% or pyrethrins as first line for head lice when resistance to these products is not suspected. Lindane is no longer recommended by the AAP. Dr. Slivka motioned to approve and accept Provider Synergies' recommendations with the addition of Ulesfia as a preferred agent. Dr. Thompson seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Eurax (Topical), Ovide (Topical), permethrin (Topical), Ulesfia (Topical)*
- **OFF Medicaid PDL:** *Lindane (Topical), Malathion (Topical), Natroba (Topical)*

Antivirals, Oral

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Valtrex is now available as a generic. The 2010 CDC STD recommendations for genital herpes do not differentiate amongst the available oral options. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Stella Cretella seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *acyclovir (Oral), amantadine (Oral), Relenza (Inhalation), rimantidine (Oral), Tamiflu (Oral), Valtrex (Oral)*
- **OFF Medicaid PDL:** *famciclovir (Oral), Famvir (Oral), valacyclovir (Oral)*

Antivirals, Topical

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 2010 CDC STD recommendations for genital herpes prefer oral therapy over topical. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Larry Sobol seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Denavir (Topical), Zovirax Ointment (Topical)*
- **OFF Medicaid PDL:** *Xerese (Topical), Zovirax Cream (Topical)*

Beta-Blockers

Chris Andrews presented the evaluation and recommendation for this class. It was noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *acebutolol (Oral), atenolol/chlorthalidone (Oral), betaxolol (Oral), bisoprolol/hctz (Oral), carvedilol (Oral), Innopran XL (Oral), labetolol (Oral), levatol (Oral),*

metoprolol/hctz (Oral), Metoprolol XL (Oral), nadolol/bendroflumethiazide (Oral), pindolol (Oral), propranolol/hctz (Oral), propranolol ER (Oral), sotalol (Oral), timolol (Oral)

- **OFF Medicaid PDL:** *Bystolic (Oral), Coreg CR (Oral), Toprol XL (Oral)*

Bladder Relaxant Preparations

Chris Andrews presented the evaluation and recommendation for this class. It was noted that Sanctura is now available as a generic. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *oxybutynin (Oral), Toviaz (Oral), Vesicare (Oral)*
- **OFF Medicaid PDL:** *Detrol (Oral), Detrol LA (Oral), DitropanXL (Oral), Enablex (Oral), Gelnique (Transderm.), oxybutynin ER (Oral), Oxytrol (Transderm.), Sanctura XR (Oral), Trospium (Oral)*

Bone Resorption Agents

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 1020 National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis recognize all U.S. FDA-approved medications for the prevention and/or treatment of osteoporosis as possible options. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *alendronate Tablets (Oral), Miacalcin (Nasal)*
- **OFF Medicaid PDL:** *Actonel (Oral), Actonel W/Calcium (Oral), Atelvia (Oral), Boniva (Oral), calcitonin salmon (Nasal), etidronate disodium (Oral), Evista (Oral), Forteo (Subcutane.), Fortical (Nasal), Fosamax Plus D (Oral), Fosamax Solution (Oral), Prolia (Subcutane.)*

BPH Treatments

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Dr. Slivka seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *doxazosin (Oral), finasteride (Oral), tamsulosin (Oral), terazosin (Oral), Uroxatral (Oral)*
- **OFF Medicaid PDL:** *Avodart (Oral), Cardura XL (Oral), Jalyn (Oral), Proscar (Oral), Rapaflo (Oral)*

Calcium Channel Blockers

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *amlodipine (Oral), diltiazem (Oral), felodipine ER (Oral), isradipine (Oral), nifedipine (Oral), nifedipine ER (Oral), nifedipine IR (Oral), verapamil (Oral), verapamil ER PM (Oral)*
- **OFF Medicaid PDL:** *Cardizem CD 360MG (Oral), Covera HS (Oral), diltiazem LA (Oral), Dynacirc CR (Oral), nimodipine (Oral), nisoldipine (Oral)*

Cephalosporins and Related Antibiotics

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Dr. Slivka motioned to approve and accept Provider Synergies' recommendations with the addition of Ceftin Suspension as preferred to the Medicaid PDL, with Dr. Thompson seconding the motion. The motion was passed with Both Richard Carbray and Emmett Sullivan opposing the recommendation

- **ON Medicaid PDL:** *amoxicillin/clav Tablet (Oral), amoxicillin/clav suspension (Oral), Augmentin 125 Suspension (Oral), Augmentin 250 Suspension (Oral), Cedax (Oral), cefaclor (Oral), cefadroxil (Oral), cefdinir (Oral), cefpodoxime (Oral), cefprozil (Oral), Ceftin Suspension (Oral), cefuroxime (Oral), cephalixin (Oral), Suprax (Oral)*
- **OFF Medicaid PDL:** *amoxicillin/clav XR (Oral), Cefditoren (oral), Ceftin Tablets (Oral)*

Colony Stimulating Factors

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approved all products in the class as preferred. Dr. Thompson seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Leukine (Injection), Neulasta (Injection), Neupogen (Injection)*
- **OFF Medicaid PDL:** *None*

Contraceptives, Oral

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Dr. Slivka motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Larry Sobol seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Apri (Oral), Aranelle (Oral), Aviane (Oral), Balziva (Oral), Camila (Oral), Caziant (Oral), Cryselle (Oral), Cyclofem (Oral), Desogen (Oral), Ella (Oral), Errin (Oral), Gildess FE (Oral), Jolessa (Oral) Jolivette (Oral), Junel (Oral), Junel FE (Oral), Kelnor 1-35 (Oral), Leena (Oral), Lessina (Oral), Levora-28 (Oral), Loestrin (Oral), Loestrin 24 FE (Oral), Loestrin FE (Oral), Low-Ogestrel (Oral), Lo-Ovral 28 (Oral), Luteru (Oral), Lybrel (Oral), Microgestin (Oral), Microgestin FE (Oral), Mircette (Oral), Mononessa (Oral), Necon (Oral), Nora-BE (Oral), Nordette-28 (Oral), norethindrone (Oral), norgestrel-ethiny estra (Oral), Nor-q-D (Oral), Nortrel (Oral), Ortho-Cyclen (Oral), Ortho-Novum (Oral), Ortho Tri-Cyclen (Oral), Ortho Tri-Cyclen Lo (Oral), Ovcon-35 (Oral), Ovcon-50 (Oral), Portia (Oral), Previfem (Oral), Reclipsen(Oral), Seasonale (Oral), Seasonique (Oral), Solia (Oral), Sprintec (Oral), Sronyx (Oral), Trinessa (Oral), Tri-Norinyl (Oral), Tri-Previfem (Oral), Tri-Sprintec (Oral), Trivora-28 (Oral), Velivet (Oral), Yasmin 28 (Oral), Yaz (Oral), Zovia 1-35E (Oral), Zovia 1-50E (Oral)*
- **OFF Medicaid PDL:** *Azurette (Oral), Beyaz (Oral), Femcon FE (Oral), Gianvi (Oral), Introvale (Oral), Kariva (Oral), Lo Loestrin FE (Oral), Loseasonique (Oral), Micronor (Oral), Natazia (Oral), Norinyl 1+50 (Oral), Ocella (Oral), Ogestrel (Oral), Quasense (Oral), Safyral (Oral), Tilia FE (Oral), Tri-Legest FE (Oral), Tro-Lo-Sprintec (Oral), Zarah (Oral), Zenchent (Oral)*

Erythropoiesis Stimulating Proteins

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the 2011 NCCN guidelines and the American Society of Clinical Oncology and American Society of Hematology 2010 guidelines do not distinguish amongst the available products. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Aranesp (Injection), Procrit (Injection)*
- **OFF Medicaid PDL:** *Epogen (Injection)*

Fluoroquinolones

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *ciprofloxacin Tablets (Oral), Levaquin (Oral)*
- **OFF Medicaid PDL:** *Avelox (Oral), Cipro Suspension (Oral), ciprofloxacin ER (Oral), Factive (Oral), Noroxin (Oral), ofloxacin (Oral), ProQuin XR (Oral)*

Growth Hormone

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Genotropin Pens (Injection), Norditropin Pens (Injection), Nutropin Vials (Injection), Nutropin AQ Vials (Injection), Nutropin AQ Pens (Injection),*
- **OFF Medicaid PDL:** *Humatrope Pens (Injection), Humatrope Vials (Injection), Omnitrope Pens (Injection), Omnitrope Vials (Injection), Saizen Pens (Injection), Saizen Vials (Injection), Serostim Vials (injection), Tev-Tropin Vials (Injection), Zorbtive Vials (injection)*

Hepatitis C Agents

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Pegasys (Subcutane.), Ribavirin (Oral)*
- **OFF Medicaid PDL:** *Infergen (Subcutane.), Peg-Intron (Subcutane.), Peg-Intron Redipen (Subcutane)*

Hypoglycemics, Incretins

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations and also add Janumet and Januvia as preferred products to the Medicaid PDL. Stella Cretella seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Byetta Pens (Subcutane.), Janumet (Oral), Januvia (Oral), Kombiglyze XR (Oral), Onglyza (Oral), Symlin Pens (Subcutane.), Symlin (Subcutane.)*
- **OFF Medicaid PDL:** *Victoza (Subcutane.)*

Hypoglycemics, Insulins

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Stella Cretella seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Humalog (Subcutane.), Humalog Mix (Subcutane.), Humalog Mix Pens (Subcutane.), Humalog Pens (Subcutane.), Humulin (Subcutane.), Humulin Pens (Subcutane.), Lantus (Subcutane.), Lantus Pens (Subcutane.), Novolin (Subcutane.), Novolin Pens (Subcutane.), Novolog (Subcutane.), Novolog Pens (Subcutane.), Novolog Mix 70/30 (Subcutane.), Novolog Mix 70/30 Pens (Subcutane.)*
- **OFF Medicaid PDL:** *Apidra (Subcutane.), Apidra Pens (Subcutane.), Levemir (Subcutane.), Levemir Pens (Subcutane.)*

Hypoglycemics, Meglitinides

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Stella Cretella seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Prandin (Oral), Starlix (Oral)*
- **OFF Medicaid PDL:** *nateglinide (Oral), Prandimet (Oral)*

Hypoglycemics, TZD

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Actos (Oral), Avandia (Oral)*
- **OFF Medicaid PDL:** *Actoplus Met (Oral), Actoplus Met XR (Oral), Avandamet (Oral), Avandaryl (Oral), Duetact (Oral)*

Immunosuppressives

Chris Andrews presented the evaluation and recommendation for this class. This is a new class on the CT PDL. Both Emmett Sullivan and Larry Sobol exempted themselves from voting. Richard Carbray motioned to accept Provider Synergies recommendations as presented, Dr. Nissanka seconding the motion. Stella Cretella, Richard Carbray, Dr. Nissanka, and Dr. Sherter voted in favor. Dr. Slivka, Dr. Thompson, and Elizabeth Rodriguez voted against the motion. The motion passed by a vote of 4 to 3.

- **ON Medicaid PDL:** *azathioprine (Oral), cyclosporine (Oral), cyclosporine modified (Oral), Gengraf (Oral), mycophenolate mofetil (Oral), Neoral (Oral), Prograf (Oral), Rapamune (Oral), Sandimmune (Oral)*
- **OFF Medicaid PDL:** *Azasan (Oral), Cellcept (Oral), Myfortic (Oral), tacrolimus (Oral), Zortress (Oral)*

Lipotropics, Other

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approve and accept Provider

Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *cholestyramine (Oral), colestipol (Oral), gemfibrozil (Oral), Niacor (Oral), Niaspan (Oral), Tricor (Oral), Trilipix (Oral)*
- **OFF Medicaid PDL:** *Antara (Oral), fenofibrate (Oral), fenofibric acid (Oral), Fenoglide (Oral), Fibricor (Oral), Lipofen (Oral), Lovaza (Oral), Triglide (Oral), Welchol (Oral), Zetia (Oral)*

Lipotropics, Statins

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Caduet (Oral), Crestor (Oral), Lescol/Lescol XL (Oral), Lipitor (Oral), lovastatin (Oral), pravastatin (Oral), Simcor (Oral), simvastatin (Oral)*
- **OFF Medicaid PDL:** *Advicor (Oral), Altoprev (Oral), Livalo (Oral), Vytorin (Oral)*

Macrolides/Ketolides

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *azithromycin (Oral), clarithromycin (Oral), clarithromycin ER (Oral), erythromycin (Oral)*
- **OFF Medicaid PDL:** *Ketex (Oral), Zmax (Oral)*

Multiple Sclerosis Agents

Chris Andrews presented the evaluation and recommendation for this class. Gilenya is a new product available in this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed by a vote of 6 to 3. Dr. Slivka, Dr. Thompson, and Elizabeth Rodriguez all opposed the motion.

- **ON Medicaid PDL:** *Avonex (Intramusc.), Betaseron (Subcutane.), Copaxone (Subcutane.)*
- **OFF Medicaid PDL:** *Ampyra (Oral), Extavia (Subcutane.), Gilenya (Oral), Rebif (Subcutane.)*

Opiate Dependence

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Suboxone Film (Sublingual), Suboxone Tablets (Sublingual)*
- **OFF Medicaid PDL:** *buprenorphine HCL (Sublingual), Subutex (Sublingual)*

PAH Agents, Oral

Chris Andrews presented the evaluation and recommendation for this class. It was noted that the boxed warning as well as warning and precautions for the risk of potential liver injury with Letairis were removed by the FDA.

Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Adcirca (Oral), Revatio (Oral), Tracleer (Oral), Ventavis (Inhalation)*
- **OFF Medicaid PDL:** *Letairis (Oral), Tyvaso (Inhalation)*

Pancreatic Enzymes

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Creon (Oral), pancrelipase (Oral), Zenpep (Oral)*
- **OFF Medicaid PDL:** *Pancreaze (Oral)*

Phosphate Binders

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Stella Cretella motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *calcium acetate (Oral), Phoslo (Oral), Renagel (Oral)*
- **OFF Medicaid PDL:** *Eliphos (Oral), Fosrenol (Oral), Renvela (Oral)*

Platelet Aggregation Inhibitors

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Richard Carbray seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Aggrenox (Oral), dipyridamole (Oral), Plavix (Oral)*
- **OFF Medicaid PDL:** *Effient (Oral), ticlodipine (Oral)*

Prenatal Vitamins

Chris Andrews presented the evaluation and recommendation for this class. This is a new class to the CT PDL. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *Cavan-Heme Omega (Oral), Citranatal Harmony (Oral), Complete Natal DHA (Oral), Completenate (Oral), Complete-RF Prenatal (Oral), Dualvit OB (Oral), Duet DHA Balanced (Oral), Ed Cyte F (Oral), Fe C (Oral), Folivane-OB (Oral), Foltabs (Oral), Icar-C Plus (Oral), Inatal Advance (Oral), Inatal GT (Oral), Inatal Ultra (Oral), M-Vit (Oral), Marnatal-F (Oral), Maternity (Oral), Natachew (Oral), Natafort (Oral), Natalvite (Oral), O-Cal FA (Oral), O-Cal Prenatal (Oral), Poly Iron PN (Oral), Poly Iron PN Forte (Oral), PR Natal 400 (Oral), Prenacare (Oral), Prenaplus (Oral), Prenatabs FA (Oral), Prenatabs Rx (Oral), Prenatal AD (Oral), Prenatal Low Iron (Oral), Prenatal Multi-vitamin W-Iron (Oral), Prenatal MR 90 FE (Oral), Prenatal Plus (Oral), Prenatal Rx (Oral), Prenate Plus (Oral), Pruet DHA (Oral), Re-Nata 29 OB (Oral), Se-Care Conceive (Oral), Se-Care Gesture (Oral), Se-Natal One (Oral), Se-Natal 19 (Oral), Se-Natal 90 (Oral), Setonet-EC (Oral), Taron-BC (Oral), Taron-C DHA (Oral), Taron-Duo EC (Oral), TriAdvance (Oral), Trimesis Rx (Oral),*

Trinatal Rx 1 (Oral), Trinate (Oral), Tri Rx (Oral), Triveen-Duo DHA (Oral), Vinate Calcium (Oral), Vinate GT (Oral), Vinate IC (Oral), Vinate-M (Oral), Vinate One (Oral), Vinate Ultra (Oral), Vinate II (Oral), Vitaspire (Oral), Zatean-CH (Oral)

- **OFF Medicaid PDL:** *Advanced Care Plus (Oral), Cavan-Alpha Kit (Oral), Cavan-EC Sod DHA (Oral), Cavan One Omega (Oral), Citracal Prenatal 90+DHA (Oral), Citranatal Assure (Oral), Citranatal B-Calm (Oral), Citranatal DHA (Oral), Citranatal 90 DHA (Oral), Citranatal RX (Oral), Combi RX (Oral), Concept OB (Oral), Corenate-DHA (Oral), Docosavit (Oral), Duet DHA Complete (Oral), Duet DHA with Ferrazone (Oral), Duet Stuartnatal (Oral), Edge OB (Oral), Elite-OB (Oral), Elite-OB 400 (Oral), Elite OB DHA (Oral), Femecal OB (Oral), Folbecal (Oral), Folcal DHA (Oral), Folcaps Care One (Oral), Folcaps Omega-3 (Oral), Folinatal Plus B (Oral), Folivane-PRX DHA NF (Oral), Folivane-EC Calcium DHA NF (Oral), Foltabs 90 Plus DHA (Oral), Foltabs Prenatal Plus DHA (Oral), Gesticare DHA (Oral), ICAR-C Plus SR (Oral), Infanate DHA (Oral), Maxinate (Oral), Multinatal Plus (Oral), Multi-Nate DHA Extra (Oral), Multi-Nate 30 DHA (Oral), Natelle-EZ (Oral), Natelle One (Oral), Natelle Plus (Oral), Navatab + DHA (Oral), Neevo DHA (Oral), Neevo (Oral), Nexa Select (Oral), OB Compete (Oral), OB Complete DHA (Oral), OB Complete One (Oral), OB Complete 400 (Oral), OB Complete Premier (Oral), OB + DHA (Oral), OB 90 + DHA (Oral), OB-Natal One (Oral), Paire OB Plus DHA (Oral), PNV-DHA (Oral), PNV-DHA + Docusate (Oral), PNV-Select (Oral), PNV-Total (Oral), Precare Premier (Oral), Prefera OB (Oral), Prefera-OB One (Oral), Prefera-OB Plus DHA (Oral), Prenatal 1-1 (Oral), Prenatal-U (Oral), Prenatal Z (Oral), Prenafirst (Oral), Prenate DHA (Oral), Prenate Elite (Oral), Prenate Essential (Oral), Prenexa (Oral), Prenexa Premiere (Oral), Preque 10 (Oral), Primacare One (Oral), PR Natal 400 EC (Oral), PR Natal 430 (Oral), PR Natal 430 EC (Oral), PR Natal 440 EC (Oral), Prenatal 19 (Oral), Pruet DHA EC (Oral), Renate DHA (Oral), Rovin-NV DHA (Oral), Rovin-NV (Oral), Se-Care (Oral), Se-Plete DHA (Oral), Se-Tan DHA (Oral), Select-OB (Oral), Select-OB + DHA (Oral), Setonet (Oral), Taron EC Calcium (Oral), Taron-EC Cal (Oral), Taron-Prex Prenatal (Oral), Tricare (Oral), TriCare DHA (Oral), Triveen-One (Oral), Triveen-Ten (Oral), Triveen-PRX RNF (Oral), Ultimatecare Combo (Oral), Ultimatecare Advantage (Oral), Ultimatecare One (Oral), Ultimatecare One NF (Oral), Vinacal (Oral), Vitanatal OB + DHA (Oral), Vinate Care (Oral), Vinate C (Oral), Vinate AZ (Oral), Vinate AZ Extra (Oral), Vinate PN Care (Oral), Vitafof-OB (Oral), Vitafof-OB+DHA (Oral), Vitafof-PN (Oral), Vitaphil + DHA (Oral), Viva DHA (Oral), Zatean-PN (Oral), Zatean-PN DHA (Oral), Zatean-PN Plus (Oral)*

Proton Pump Inhibitors

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Dr. Slivka motioned to approve and accept Provider Synergies' recommendations and add Prilosec Suspension as a preferred product for the Medicaid PDL. Dr. Thompson seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Dexilant (Oral), Nexium (Oral), Prilosec Suspension (Oral)*
- **OFF Medicaid PDL:** *Aciphex (Oral), lansoprazole capsules (Oral), lansoprazole solutabs (Oral), Nexium Suspension (Oral), omeprazole (Oral), omeprazole/sodium bicarbonate (Oral), pantoprazole (Oral), Prevacid (Oral), Prevacid Solutab (Oral), Protonix Suspension (Oral)*

Skeletal Muscle Relaxants

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Larry Sobol motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Stella Cretella seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *baclofen (Oral), carisoprodol (Oral), carisoprodol compound (Oral), chlorzoxazone (Oral), cyclobenzaprine (Oral), methocarbamol (Oral)*
- **OFF Medicaid PDL:** *Amrix (Oral), dantrolene Sodium (Oral), Fexmid (Oral), metaxalone (Oral), orphenadrine (Oral), orphenadrine Compound (Oral), Skelaxin (Oral), Soma 250mg (Oral), tizanidine (Oral), Zanaflex Capsules (Oral)*

Tetracyclines

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Richard Carbray motioned to approve and accept Provider Synergies' recommendations as presented for the Medicaid PDL, with Emmett Sullivan seconding. The motion was passed unanimously.

- **ON Medicaid PDL:** *doxycycline hyclate (Oral), doxycycline monohydrate (Oral), minocycline capsules (Oral), tetracycline (Oral)*
- **OFF Medicaid PDL:** *Adoxa CK (Oral), Adoxa TT (Oral), demeclocycline (Oral), doxycycline hyclate DR (Oral), Doryx (Oral), minocycline tablets (Oral), minocycline ER (Oral), Oracea (Oral), Solodyn (Oral), vibramycin suspension (Oral)*

Ulcerative Colitis Agents

Chris Andrews presented the evaluation and recommendation for this class. He also noted that there has been no new significant information pertaining to this class. Emmett Sullivan motioned to approve and accept Provider Synergies' recommendations and add Lialda and Pentasa as preferred products to the Medicaid PDL. Larry Sobol seconded the motion. The motion was passed unanimously.

- **ON Medicaid PDL:** *Apriso (Oral), Asacol (Oral), Canasa (Rectal), Lialda (Oral), mesalamine (Rectal), Pentasa (Oral), sulfasalazine (Oral),*
- **OFF Medicaid PDL:** *AsacolHD (Oral), balsalazide (Oral), dipentum (Oral), SF Rowasa (Rectal)*

Committee Discussion Topics:

Carl suggests getting written recommendations from medical societies for certain classes of drugs. Next classes for review will be circulated soon to get input as to what classes we need to solicit recommendations for.

Recommendations for next class reviews:

Provider Synergies recommended the following classes be reviewed at the next P&T meeting:

ALZHEIMER'S AGENTS
ANALGESICS/ANESTHETICS, TOPICAL
ANTICONSULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTIHISTAMINES, MINIMALLY SEDATING
ANTIHYPERTENSIVES, ORAL
ANTIPARKINSON'S AGENTS
ANTIPSYCHOTICS
BILE SALTS
BOTULINUM TOXINS
BRONCHODILATORS, ANTICHOLINERGIC
BRONCHODILATORS, BETA AGONIST
COUGH AND COLD, COLD
COUGH AND COLD, NARCOTIC
COUGH AND COLD, NON-NARCOTIC
CYTOKINE AND CAM ANTAGONISTS
EPINEPHRINE, SELF-INJECTED
FIBROMYALGIA AGENTS
GLUCOCORTICOIDs, INHALED
IMMUNOMODULATORS, ATOPIC DERMATITIS
INTRANASAL RHINITIS AGENTS
LEUKOTRIENE MODIFIERS
NSAIDS
ONCOLOGY AGENTS, ORAL
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS

OPHTHALMIC ANTIINFLAMMATORIES
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
SEDATIVE HYPNOTICS
SMOKING CESSATION
STEROIDS, TOPICAL - HIGH POTENCY
STEROIDS, TOPICAL – LOW POTENCY
STEROIDS, TOPICAL - MEDIUM POTENCY
STEROIDS, TOPICAL – VERY HIGH POTENCY
STIMULANTS AND RELATED AGENTS

Schedule next meeting:

Committee members agreed on Thursday, November 3, 2011 for the next P & T meeting

Meeting adjourned at 9:30 pm